Q-omics provides the consensus-scored HNRNPA1P35 profile across patient tissues and cancer cell-line models. HNRNPA1P35 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HNRNPA1P35 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, HNRNPA1P35 RNA expression shows 17,330 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where HNRNPA1P35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPA1P35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPA1P35 survival associations across molecular data types. HNRNPA1P35 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPA1P35 RNA expression–survival associations across cancer types. High HNRNPA1P35 expression shows unfavorable associations in ACC, KIRP and ESCA, but favorable associations in KIRC, THCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HNRNPA1P35 RNA expression.
This table summarizes HNRNPA1P35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPA1P35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPA1P35 shows higher tumor expression in COAD, LUAD, LIHC, KIRP, LUSC and HNSC. The COAD box plot shows higher HNRNPA1P35 RNA expression in tumor versus normal tissue (log2 FC = +0.433, t-test p < 0.001).
This table shows molecular features associated with HNRNPA1P35 in patient tissues and cancer cell lines. In patient samples, HNRNPA1P35 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
